Sustained reductions in LDL-C, apoB and Lp(a) were reported with the ANGPTL3 GalNac RNAi, zodasiran, in patients with homozygous familial hypercholesterolaemia (HoFH) in the GATEWAY trial open label extension (OLE).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
